QUANTASETM NEONATAL G6PD DEFICIENCY SCREENING (BLOOD SPOT CONTROLS) - COFEPRIS Registration 1439R2018 SSA
Access comprehensive regulatory information for QUANTASETM NEONATAL G6PD DEFICIENCY SCREENING (BLOOD SPOT CONTROLS) (QUANTASETM NEONATAL G6PD DEFICIENCY SCREENING (BLOOD SPOT CONTROLS)) in the Mexico medical device market through Pure Global AI's free database. This Clase I medical device is registered under COFEPRIS analysis ID 1439R2018 SSA and manufactured by BIO-RAD, S.A.. The device was registered on June 07, 2018.
This page provides complete registration details including product type (III. DIAGNOSTIC AGENTS), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.
LOS CONTROLES DE MANCHA DE SANGRE SE EMPLEAN COMO REFERENCIA DE DESEMPEÑO E IMITAN LAS CONDICIONES DE UNA MUESTRA PARA EVALUAR EN PROCESO EN CONJUNTO CON EL KIT QUANTASETM NEONATAL G6PD DEFICIENCY SCREENING. AGENTES DE DIAGNÓSTICO. PARA USO EXCLUSIVO EN
BLOOD STAIN CONTROLS ARE USED AS A PERFORMANCE BENCHMARK AND MIMIC THE CONDITIONS OF A SAMPLE TO BE EVALUATED IN PROCESS IN CONJUNCTION WITH THE QUANTASETM NEONATAL G6PD DEFICIENCY SCREENING KIT. DIAGNOSTIC AGENTS. FOR EXCLUSIVE USE IN